The revenue miss and lowered top-end guidance are modest negatives, but the ongoing strategic alternatives review (including a potential sale) provides a counterbalancing catalyst. Watch for any announcement regarding the strategic review outcome, which could include a sale of the company.
Price Chart
Executive Summary
Bioventus reported Q3 2026 revenue of $142.4M (+3% YoY), slightly below the $149.5M consensus, and non-GAAP EPS of $0.17, in line with the $0.17 consensus. The company narrowed its full-year net sales guidance to $590M-$595M (from $600M-$610M), reflecting ~4-5% growth, while reaffirming adjusted EPS of $0.75-$0.79. The ongoing strategic alternatives review, initiated after an unsolicited acquisition proposal in Q2, continues with no set timetable.
Key Financial Metrics
Key Facts
- Q3 2026 revenue of $142.4M, up 3% YoY from $138.7M
- GAAP diluted EPS of $0.08 vs $0.05 in prior year
- Non-GAAP EPS of $0.17 vs $0.15 in prior year, in line with $0.17 consensus
- Revenue of $142.4M missed consensus of $149.5M
- Full-year net sales guidance narrowed to $590M-$595M from $600M-$610M
- Adjusted EPS guidance reaffirmed at $0.75-$0.79
- Adjusted EBITDA of $28.4M, up 7% YoY from $26.6M
- Cash from operations of $20.7M in Q3
- Company continues to review strategic alternatives after receiving unsolicited acquisition proposal in Q2
- Made $15M discretionary principal prepayment on term loan in Q3
Financial Impact
Revenue miss of ~$7.1M vs consensus; guidance narrowed lower by $10M-$15M at the top end
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Pain Treatments | $71.3M | +6.2% |
| Surgical Solutions | $50.5M | +0.7% |
| Restorative Therapies | $20.6M | -3.4% |
Risk Factors
- Revenue growth slowing to 3% in Q3 vs 4% in Q2 and 6-7% full-year guidance initially
- Restorative Therapies segment declining 3.4% YoY, driven by EXOGEN weakness
- No timetable for strategic alternatives review; process could be protracted or yield no transaction
- Cash and cash equivalents declined to $30.7M from $51.2M at year-end 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001665988-26-000050 |
| Document: bvs-20261102.htm | 0001665988-26-000050 |
| Document: 0001665988-26-000050-index-headers.html | 0001665988-26-000050 |
| Document: 0001665988-26-000050-index.html | 0001665988-26-000050 |
| Document: 0001665988-26-000050.txt | 0001665988-26-000050 |
| 8-K Data (Synthetic) | 0001665988-26-000050 |
Track record
18 reports on BVS
2 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
- Nov 2, 202614d ago 8-K Neutral 5/10 Viewing No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $10.95 Now $10.46 −4.43% settles Feb 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
- Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 No price data
- Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
- Jun 2, 202623w ago Press Release Bearish 6/10 Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers